Serum IL-15 in patients with early systemic sclerosis: a potential novel marker of lung disease
(2007) In Arthritis Research and Therapy 9(5).- Abstract
- ABSTRACT: The pathogenesis of systemic sclerosis (SSc) is characterized by autoimmunity, vasculopathy and fibrosis. IL-15 is a pleiotropic cytokine that has impact on immune, vascular and connective tissue cells. We therefore investigated IL-15 in the circulation of patients with early SSc and explored possible associations of serum IL-15 with vasculopathy and fibrosis. Serum levels of IL-15 were analysed in 63 consecutive patients with SSc of disease duration less than 4 years and without disease-modifying treatment. Thirty-three age-matched healthy control individuals were enrolled. Serum IL-15 levels were increased in the sera of SSc patients compared with that of healthy control individuals (P < 0.01). Serum IL-15 levels correlated... (More)
- ABSTRACT: The pathogenesis of systemic sclerosis (SSc) is characterized by autoimmunity, vasculopathy and fibrosis. IL-15 is a pleiotropic cytokine that has impact on immune, vascular and connective tissue cells. We therefore investigated IL-15 in the circulation of patients with early SSc and explored possible associations of serum IL-15 with vasculopathy and fibrosis. Serum levels of IL-15 were analysed in 63 consecutive patients with SSc of disease duration less than 4 years and without disease-modifying treatment. Thirty-three age-matched healthy control individuals were enrolled. Serum IL-15 levels were increased in the sera of SSc patients compared with that of healthy control individuals (P < 0.01). Serum IL-15 levels correlated with impaired lung function, assessed both by the vital capacity (P < 0.05) and by the carbon monoxide diffusion capacity (P < 0.05). The association between IL-15 and the vital capacity remained after multiple linear regression analysis. Patients with intermediate serum IL-15 levels had a higher prevalence of increased systolic pulmonary pressure compared with patients with either low or high serum IL-15 levels (P < 0.05). Moreover, increased serum IL-15 levels were associated with a reduced nailfold capillary density in multivariable logistic regression analysis (P < 0.01). Serum IL-15 levels also correlated inversely with the systolic blood pressure (P < 0.01). We conclude that IL-15 is associated with fibrotic as well as vascular lung disease and vasculopathy in early SSc. IL-15 may contribute to the pathogenesis of SSc. IL-15 could also be a candidate biomarker for pulmonary involvement and a target for therapy in SSc. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1141053
- author
- Wuttge, Dirk LU ; Wildt, Marie LU ; Geborek, Pierre LU ; Wollheim, Frank LU ; Scheja, Agneta LU and Åkesson, Anita LU
- organization
- publishing date
- 2007
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Arthritis Research and Therapy
- volume
- 9
- issue
- 5
- article number
- 85
- publisher
- BioMed Central (BMC)
- external identifiers
-
- pmid:17784951
- wos:000252468400008
- scopus:35748952537
- pmid:17784951
- ISSN
- 1478-6362
- DOI
- 10.1186/ar2284
- language
- English
- LU publication?
- yes
- id
- 1ba0553b-ee76-4637-9c43-84c4f42ab6fb (old id 1141053)
- date added to LUP
- 2016-04-04 08:33:52
- date last changed
- 2022-03-30 23:44:22
@article{1ba0553b-ee76-4637-9c43-84c4f42ab6fb,
abstract = {{ABSTRACT: The pathogenesis of systemic sclerosis (SSc) is characterized by autoimmunity, vasculopathy and fibrosis. IL-15 is a pleiotropic cytokine that has impact on immune, vascular and connective tissue cells. We therefore investigated IL-15 in the circulation of patients with early SSc and explored possible associations of serum IL-15 with vasculopathy and fibrosis. Serum levels of IL-15 were analysed in 63 consecutive patients with SSc of disease duration less than 4 years and without disease-modifying treatment. Thirty-three age-matched healthy control individuals were enrolled. Serum IL-15 levels were increased in the sera of SSc patients compared with that of healthy control individuals (P < 0.01). Serum IL-15 levels correlated with impaired lung function, assessed both by the vital capacity (P < 0.05) and by the carbon monoxide diffusion capacity (P < 0.05). The association between IL-15 and the vital capacity remained after multiple linear regression analysis. Patients with intermediate serum IL-15 levels had a higher prevalence of increased systolic pulmonary pressure compared with patients with either low or high serum IL-15 levels (P < 0.05). Moreover, increased serum IL-15 levels were associated with a reduced nailfold capillary density in multivariable logistic regression analysis (P < 0.01). Serum IL-15 levels also correlated inversely with the systolic blood pressure (P < 0.01). We conclude that IL-15 is associated with fibrotic as well as vascular lung disease and vasculopathy in early SSc. IL-15 may contribute to the pathogenesis of SSc. IL-15 could also be a candidate biomarker for pulmonary involvement and a target for therapy in SSc.}},
author = {{Wuttge, Dirk and Wildt, Marie and Geborek, Pierre and Wollheim, Frank and Scheja, Agneta and Åkesson, Anita}},
issn = {{1478-6362}},
language = {{eng}},
number = {{5}},
publisher = {{BioMed Central (BMC)}},
series = {{Arthritis Research and Therapy}},
title = {{Serum IL-15 in patients with early systemic sclerosis: a potential novel marker of lung disease}},
url = {{http://dx.doi.org/10.1186/ar2284}},
doi = {{10.1186/ar2284}},
volume = {{9}},
year = {{2007}},
}